Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy. Trilaciclib was first described in the literature in 2016. Trilaciclib was granted FDA approval on 12 February 2021.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Trilaciclib
Drug Overview
What is Trilaciclib?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Trilaciclib is a chemical substance that may be handled in pharmaceutical and chemical manufacturing. The precise toxicological profile and occupational exposure considerations should be established from reliable substance-specific evidence rather than inferred from the name alone. Reviewing the available data and intended handling conditions can support a documented assessment of worker protection and potential cross-contamination risk.
A PDE or ADE sets a health-based limit on daily exposure to Trilaciclib from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
Potential carryover of Trilaciclib is evaluated by considering the health-based limit, the manufacturing and cleaning process, shared equipment, residue pathways, and the analytical methods used to detect residues. The assessment should account for the actual use scenario and applicable quality requirements. A PDE can inform the health-based component of the evaluation, but final controls and acceptance criteria require a broader, documented risk assessment.
The physical form in which Trilaciclib is handled may affect the potential for exposure and the controls needed in the workplace. Powders, liquids, solutions, and other forms can behave differently during dispensing, transfer, sampling, or cleaning. The occupational assessment should consider the actual process and potential exposure routes, while keeping the toxicological hazard assessment distinct from the practical evaluation of exposure likelihood.
For Trilaciclib, pharmacological information and toxicological findings should be considered together when they are relevant to the intended assessment. The evaluator should distinguish therapeutic effects from adverse effects, consider the quality of the supporting studies, and identify the critical endpoint for the exposure assessment. The final rationale should explain how the selected evidence supports the conclusion and where uncertainty remains.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Trilaciclib in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
A toxicological assessment of Trilaciclib reviews the available evidence to characterize potential hazards and support proportionate risk management. The findings can inform health-based exposure limits, handling practices, containment measures, and cross-contamination controls. The conclusions should reflect the quality and relevance of the available data, clearly document uncertainties, and avoid treating data gaps as evidence that a substance is safe.
The assessment of Trilaciclib may consider relevant repeat-dose toxicity, genotoxicity, reproductive and developmental toxicity, carcinogenicity, pharmacology, and other evidence where available. The data selected should be relevant to the substance and the intended assessment. The critical effect and point of departure should be supported by a documented scientific rationale, with limitations and uncertainties explained transparently.
Uncertainty factors in an assessment of Trilaciclib account for matters such as differences between test species and humans, variability among people, study duration, study quality, and gaps in the evidence. The factors should be selected individually and justified scientifically rather than applied automatically. The report should show how the factors influence the final health-based limit and identify key assumptions.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Trilaciclib to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
